Universal chimeric antigen receptor T cells specific for CD22
US11690873B2 · kind B2 · utility
2Cited by
20References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2018 |
| Grant date | Jul 4, 2023 |
| Priority date | — |
| Expiry date | Nov 3, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.